This report sets out to help the reader understand how sophisticated pharmaceutical investors value life sciences companies. Our research shows that, while there are various ways to value biotechnology assets, big pharma primarily uses the Risk Adjusted NPV (rNPV) method.

To learn about this and other methods, download the detailed guide by filling out the following form.